Skip to main content

4 Result(s)

within F Barlési Remove this filter

and

  1. No Access

    Article

    Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet

    Successful immunotherapy is restricted to some cancers only, and combinatorial strategies with other drugs could help to improve their efficacy. Here, we monitor T cells in NSCLC model after treatment with cyt...

    G. Sicard, D. Protzenko, S. Giacometti, F. Barlési… in British Journal of Cancer (2023)

  2. No Access

    Chapter

    Diagnostic et bilan d’extension des cancers broncho-pulmonaires

    Les cancers broncho-pulmonaires constituent la 4e cause de cancer en France avec environ 30 600 cas, mais la 1re cause de mortalité par cancer avec 26 600 décès annuels (1). Avec une survie globale ne dépassant p...

    F. Barlési in Oncologie thoracique (2011)

  3. Article

    Open Access

    Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung

    This study investigated the relation between positive thyroid transcription factor 1 (TTF1) staining and survival of patients affected by primary adenocarcinoma (ADC) of the lung. Pathological tissue from cons...

    F Barlési, D Pinot, A LeGoffic, C Doddoli, B Chetaille… in British Journal of Cancer (2005)

    Download PDF (1798 KB) View Article

  4. Article

    Open Access

    CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy

    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) as gefitinib emerged as an accepted treatment in second- or third-line setting in NSCLC. However, clinical surrogate markers of EGFR-TKI...

    F Barlési, C Tchouhadjian, C Doddoli, J-P Torre, P Astoul… in British Journal of Cancer (2005)

    Download PDF (79 KB) View Article